Analytical Data
-
Gene name
IL-18
- Application
-
Alternative Names
Iboctadekin Interferon gamma-inducing factor
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE. as determined by SDS-PAGE.
-
Uniprot
Q14116
-
Expression Region
1-193aa
-
Molecular Weight
22.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-18 (IL-18) is a pro-inflammatory cytokine that plays a crucial role in the immune response, particularly in the regulation of T and natural killer (NK) cell functions. It is primarily produced by macrophages and dendritic cells and is known to enhance the production of other cytokines, such as interferon-gamma (IFN-γ), which is vital for the activation of the immune system against infections and tumors. Given its significant role in mediating immune responses, IL-18 has garnered attention in both basic and clinical research, particularly in the context of autoimmune diseases, cancer, and infectious diseases. Recent studies have highlighted its potential as a therapeutic target, leading to the development of recombinant IL-18 proteins for clinical applications. These recombinant forms are being explored for their ability to modulate immune responses, boost vaccine efficacy, and serve as adjuvants in cancer immunotherapy. The investigation of IL-18's mechanisms and its recombinant protein's effects on various immune cell populations is critical for understanding its functions and therapeutic potential. Additionally, IL-18's ability to synergize with other cytokines offers exciting opportunities for combination therapies that could enhance patient outcomes in various disease contexts. As such, research into IL-18 recombinant proteins continues to be a dynamic and promising area within immunology and therapeutic development.
